Back to Search Start Over

Budget Impact Analysis of Treatment Flow Optimization in Epilepsy Patients: Estimating Potential Impacts with Increased Referral Rate to Specialized Care

Authors :
Masaki Iwasaki
Takashi Saito
Akiko Tsubota
Tatsunori Murata
Yuta Fukuoka
Kazutaka Jin
Source :
Journal of Health Economics and Outcomes Research, Vol 8, Iss 1 (2021)
Publication Year :
2021
Publisher :
Columbia Data Analytics, LLC, 2021.

Abstract

**Objectives:** We developed a Markov model to simulate a treatment flow of epilepsy patients who refer to specialized care from non-specialized care, and to surgery from specialized care for estimation of patient distributions and expenditures caused by increasing the referral rate for specialized care. **Methods:** This budget impact analysis of treatment flow optimization in epilepsy patients was performed as a long-term simulation using the Markov model by comparing the current treatment flow and the optimized treatment flow. In the model, we simulated the prognosis of new onset 5-year-old epilepsy patients (assuming to represent epilepsy occurring between 0 and 10 years of age) treated over a lifetime period. Direct costs of pharmacotherapies, management fees and surgeries are included in the analysis to evaluate the annual budget impact in Japan. **Results:** In the current treatment flow, the number of refractory patients treated with four drugs by non-specialized care were estimated as 8766 and yielded JPY5.8 billion annually. However, in the optimized treatment flow, the number of patients treated with four drugs by non-specialized care significantly decreased and who continued the monotherapy increased. The costs for the four-drug therapy by non-specialized care were eliminated. Hence cost-saving of JPY9.5 billion (-5% of the current treatment flow) in total national expenditures would be expected. **Conclusion:** This study highlights that any policy decision-making for referral optimization to specialized care in appropriate epilepsy patients would be feasible with a cost-savings or very few budget impacts. However, important information in the decision-making such as transition probability to the next therapy or excuse for sensitive limitations is not available currently. Therefore, further research with reliable data such as big data analysis or a national survey with real-world treatment patterns is needed.

Details

Language :
English
ISSN :
23272236
Volume :
8
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Health Economics and Outcomes Research
Publication Type :
Academic Journal
Accession number :
edsdoj.5136535034b94ccaa8ca9c4451f351cd
Document Type :
article
Full Text :
https://doi.org/10.36469/jheor.2021.24061